Kovack Advisors’s Alterity Therapeutics ATHE Stock Holding History

Kovack Advisors’s Portfolio ATHE Stock Details ATHE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-257	Closed	-$17K	–	216
2015 Q1	$17K	Buy	+257	New	+$20.5K	0.01%	168

Other funds holding ATHE

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

GBA

Garrison Bradford & Associates New York $88.4M AUM 15.86% 1-Year Est. Return

CAM

Columbia Asset Management Ann Arbor, Michigan $575M AUM 29.81% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

AIM

Advantage Investment Management Cedar Rapids, Iowa $128M AUM 0.94% 1-Year Est. Return

Kovack Advisors's ATHE Position: Q2 2015 in Review

Kovack Advisors sold out of Alterity Therapeutics (ATHE) in Q2 2015, closing a stake of 257 shares — an estimated $17K sold.

Kovack Advisors first reported a position in ATHE in Q1 2015 and held it in 1 quarter. The position peaked at $17K in Q1 2015. 21 funds tracked by Wall St. Rank hold ATHE as of Q2 2015.

Kovack Advisors reported no remaining Alterity Therapeutics position as of Q2 2015 after selling out during the quarter.
Kovack Advisors sold 257 Alterity Therapeutics shares in Q2 2015, an estimated $17K.
Kovack Advisors first reported a position in Alterity Therapeutics in Q1 2015 and held it in 1 quarter.
Kovack Advisors's Alterity Therapeutics position peaked at $17K in Q1 2015.
21 funds tracked by Wall St. Rank held Alterity Therapeutics as of Q2 2015.

Based on Kovack Advisors's 13F filing for Q2 2015, filed 6 Nov 2018.